Tongue cancer secondary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Tongue cancer}} {{CMG}} ==Overview== ==References== {{reflist|2}}")
 
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Tongue cancer}}
{{Tongue cancer}}
{{CMG}}
{{CMG}}; {{AE}} {{Simrat}} {{MAD}}


==Overview==
==Overview==
Secondary prevention strategies following tongue cancer include monthly follow-ups for the first 12-18 months following therapy. Drugs such as synthetic [[Retinoid|retinoids]], [[Non-steroidal anti-inflammatory drug|non-steroidal antiinflammatory drugs]], [[EGFR]] inhibition, and [[human papilloma virus]] related oropharyngeal carcinoma vaccine can be used as a secondary [[Chemoprevention|chemopreventive]] agents.
==Secondary Prevention==
*Postoperative patients are monitored monthly for the first 12-18 months.
*In patients who undergo nonsurgical treatment, follow-up diagnostic imaging studies are recommended in the first 6 months.
*[[Beta-carotene]] and [[vitamin E]] are used as secondary [[Chemoprevention|chemopreventive]] agents.<ref name="pmid15812073">{{cite journal| author=Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F et al.| title=A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. | journal=J Natl Cancer Inst | year= 2005 | volume= 97 | issue= 7 | pages= 481-8 | pmid=15812073 | doi=10.1093/jnci/dji095 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15812073  }}</ref>
==== '''Synthetic retinoids''' ====
*[[Premalignant condition|Premalignant lesions]] have low levels of the nuclear [[Retinoid receptor|retinoid receptors]] which control normal growth and differentiation. Retinoid have anti[[Angiogenesis|angiogenic]] activity.<ref name="pmid10626810">{{cite journal| author=Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC| title=Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. | journal=Cancer Res | year= 1999 | volume= 59 | issue= 24 | pages= 6178-84 | pmid=10626810 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10626810  }}</ref>
*Synthetic [[retinoids]] response rates are 59 to 92%.
==== Non-steroidal antiinflammatory drugs ====
*Intake of [[nonsteroidal antiinflammatory drugs]] prevents the development of intraepithelial [[squamous cell carcinomas]] especially in the [[colon]] and [[rectum]] due to inhibition [[COX-2]] and diminished synthesis of [[prostaglandins]].<ref name="pmid9850093">{{cite journal| author=Lingen MW, Polverini PJ, Bouck NP| title=Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. | journal=Cancer Res | year= 1998 | volume= 58 | issue= 23 | pages= 5551-8 | pmid=9850093 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9850093  }}</ref>
==== '''EGFR inhibition''' ====
*[[EGFR|Endothelial growth factor receptor]] (EGFR) is highly expressed in [[Squamous cell carcinoma|SCC]] of the tongue, suggesting that [[EGFR]] inhibition may be effective in these [[tumors]].<ref name="pmid1313356">{{cite journal| author=Klijn JG, Berns PM, Schmitz PI, Foekens JA| title=The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. | journal=Endocr Rev | year= 1992 | volume= 13 | issue= 1 | pages= 3-17 | pmid=1313356 | doi=10.1210/edrv-13-1-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1313356  }}</ref>
==== '''Human papilloma virus related oropharyngeal carcinoma''' vaccine  ====
*The [[E6 - protein|E6]] and E7 HPV viral proteins in [[Human papillomavirus|HPV]] 16 are responsible for promoting [[cell cycle]] progression and [[viral]] [[DNA replication]] in differentiated normal [[mucosal]] epithelial cells.
*While [[E6 - protein|E6 protein]] binds to [[Tumor suppressor gene|p53 tumor suppressor protein]] and induces its degradation, the E7 protein [[Ubiquitination|ubiquitinates]] the [[retinoblastoma]] [[Tumor suppressor gene|tumor suppressor protein.]]
*This process leads to driving the [[mucosal]] cells into [[S phase]] and induces cellular [[DNA synthesis]].<ref name="pmid23953776">{{cite journal| author=Rampias T, Sasaki C, Psyrri A| title=Molecular mechanisms of HPV induced carcinogenesis in head and neck. | journal=Oral Oncol | year= 2014 | volume= 50 | issue= 5 | pages= 356-63 | pmid=23953776 | doi=10.1016/j.oraloncology.2013.07.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23953776  }}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}

Latest revision as of 00:16, 3 December 2017

Tongue cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tongue cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tongue cancer secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tongue cancer secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tongue cancer secondary prevention

CDC on Tongue cancer secondary prevention

Tongue cancer secondary prevention in the news

Blogs on Tongue cancer secondary prevention

Directions to Hospitals Treating Tongue cancer

Risk calculators and risk factors for Tongue cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Secondary prevention strategies following tongue cancer include monthly follow-ups for the first 12-18 months following therapy. Drugs such as synthetic retinoids, non-steroidal antiinflammatory drugs, EGFR inhibition, and human papilloma virus related oropharyngeal carcinoma vaccine can be used as a secondary chemopreventive agents.

Secondary Prevention

  • Postoperative patients are monitored monthly for the first 12-18 months.
  • In patients who undergo nonsurgical treatment, follow-up diagnostic imaging studies are recommended in the first 6 months.

Synthetic retinoids

Non-steroidal antiinflammatory drugs

EGFR inhibition 

Human papilloma virus related oropharyngeal carcinoma vaccine

References

  1. Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F; et al. (2005). "A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients". J Natl Cancer Inst. 97 (7): 481–8. doi:10.1093/jnci/dji095. PMID 15812073.
  2. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC (1999). "Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines". Cancer Res. 59 (24): 6178–84. PMID 10626810.
  3. Lingen MW, Polverini PJ, Bouck NP (1998). "Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma". Cancer Res. 58 (23): 5551–8. PMID 9850093.
  4. Klijn JG, Berns PM, Schmitz PI, Foekens JA (1992). "The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients". Endocr Rev. 13 (1): 3–17. doi:10.1210/edrv-13-1-3. PMID 1313356.
  5. Rampias T, Sasaki C, Psyrri A (2014). "Molecular mechanisms of HPV induced carcinogenesis in head and neck". Oral Oncol. 50 (5): 356–63. doi:10.1016/j.oraloncology.2013.07.011. PMID 23953776.

Template:WH Template:WS